Skip to main content

Table 1 Patients’ characteristics and survival times according to clinicopathological factors

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

Characteristics   n % Median (months) 3-Y-S (%) 5-Y-S (%) p
a: All patients        
Sex Male 431 75.7 66.0 60.8 52.6 0.637
  Female 138 24.3 66.0 57.0 52.7  
Localization AEG 351 61.7 74.2 60.4 52.4 0.81
UICC 7th edition Gastric cancer 212 37.3 62.2 58.7 52.3  
Localization AEG I 143 25.1 108.0 63.0 55.5 0.288
UICC 6th edition AEG II/III + GC 426 74.9 64.1 58.9 51.8  
Laurén intestinal 320 56.2 78.8 65.1 57.2 0.029
  non-intestinal 234 41.1 47.1 54.8 48.2  
Grading low grade 166 29.2 108.0 69.3 64.7 0.012
  high grade 395 69.4 54.1 56.4 47.8  
pT pT0 38 6.7 n.r. 85.6 76.4 <0.001
  pT1 52 9.1 n.r. 83.5 83.5  
  pT2 276 48.5 85.6 68.7 62.5  
  pT3 184 32.2 26.7 37.4 25.4  
  pT4 19 3.3 14.2 5.3 0.0  
pN pN0 242 42.5 101.9 76.8 69.6 <0.001
  pN1 201 35.3 33.3 48.2 39.4  
  pN2 74 13 26.3 41.3 34.6  
  pN3 28 4.9 18.9 25.4 25.4  
  pNx 24 4.2 n.r. 78.5 78.5  
pM pM0 525 92.3 72.8 62.0 54.6 0.001
  pM1 44 7.7 23.6 36.3 32.2  
R R0 476 83.7 74.2 64.7 56.7 <0.001
  R1/R2 93 16.3 20.3 34.2 32.2  
Neoadjuvant chemotherapy yes 369 64.9 74.2 61.5 52.6 0.157
  no 200 35.1 62.2 56.8 53.1  
Characteristics   n % Median (months) 3-Y-S (%) 5-Y-S (%) p
b: Neoadjuvantly treated patients        
Sex Male 309 83.7 78.8 63.2 53.7 0.253
  Female 60 16.3 48.6 53.0 46.9  
Localization AEG 287 77.8 78.8 63.4 54.4 0.259
UICC 7th edition Gastric cancer 82 22.2 42.5 55.7 46.3  
Localization AEG I 139 37.7 108.0 62.8 55.3 0.653
UICC 6th edition AEG II/III + GC 230 62.3 66.0 61.0 51.1  
Laurén Intestinal 220 59.6 108.0 67.3 58.7 0.014
  Non-intestinal 140 37.9 40.5 54.4 44.6  
Grading Low grade 109 29.5 108.0 73.0 68.2 0.008
  High grade 254 68.8 47.1 56.8 45.3  
pT pT0 38 10.3 n.r. 85.6 76.4 <0.001
  pT1 35 9.5 n.r. 83.2 83.2  
  pT2 169 45.8 101.9 68.7 60.3  
  pT3 116 31.4 26.9 39.5 25.2  
  pT4 11 3.0 14.2 0.0 0.0  
pN pN0 157 42.5 108.0 77.4 69.3 <0.001
  pN1 142 38.5 34.0 49.0 38.6  
  pN2 39 10.6 29.1 44.1 31.6  
  pN3 17 4.6 18.9 38.5 38.5  
  pNx 14 3.8 n.r. 77.9 77.9  
pM pM0 328 88.9 82.7 65.1 55.6 <0.001
  pM1 41 11.1 23.6 33.4 28.6  
R R0 291 78.9 n.r. 69.0 58.4 <0.001
  R1/R2 78 21.1 20.3 32.7 30.4  
Clinical response Responder 105 28.5 39.2 82.6 74.2 <0.001
  Nonresponder 263 71.3 108.0 52.4 42.8  
TRG 1a,1b 104 28.2 n.r. 83.8 77.4 <0.001
  2,3 263 71.3 39.2 52.5 42.1  
Characteristics   n % Median (months) 3-Y-S (%) 5-Y-S (%) p
c: Primarily resected patients        
Sex Male 122 61.0 62.2 54.6 50.1 0.318
  Female 78 39.0 66.0 60.5 57.5  
Localization AEG 64 32.0 32.6 46.9 44.3 0.049
UICC 7th edition Gastric cancer 131 65.5 64.1 60.7 56.4  
Localization AEG I 4 2.0 n.r. 75.0 75.0 0.619
UICC 6th edition AEG II/III + GC 196 98.0 62.2 56.5 52.9  
Laurén Intestinal 100 50.0 62.2 59.8 53.4 0.807
  Non-intestinal 94 47.0 64.1 55.7 54.0  
Grading Low grade 57 28.5 62.2 61.5 55.9 0.526
  High grade 141 70.5 64.1 55.8 52.2  
pT pT0 0 0.0     <0.001
  pT1 17 8.5 n.r. 86.5 86.5  
  pT2 107 53.5 85.6 68.5 65.4  
  pT3 68 34.0 25.8 33.2 26.6  
  pT4 8 4.0 10.3 12.5 12.5  
pN pN0 85 42.5 85.6 76.0 70.2 <0.001
  pN1 59 29.5 32.0 45.4 41.6  
  pN2 35 17.5 21.7 37.9 28.4  
  pN3 11 5.5 16.1 9.1 9.1  
  pNx 10 5.0 n.r. 78.8 78.8  
pM pM0 197 98.5 62.2 56.6 52.9 0.684
  pM1 3 1.5 n.r. 66.7 66.7  
R R0 185 92.5 64.1 57.8 53.9 0.144
  R1/R2 15 7.5 18.1 44.4 0.0  
  1. MS = median survival, 3-Y-S = 3-Year-Survival, 5-Y-S = 5-Year-Survival, AEG = adenocarcinoma of the esophagogastric junction, TRG = tumor regression grade, n.r. = not reached.